Articles tagged with Drug Targets
A new combination therapy using registered drugs albendazole and antibiotics has dramatically shortened treatment time for lymphatic filariasis and onchocerciasis, reducing it from weeks to just seven days. This breakthrough could accelerate elimination of these debilitating diseases, prioritized by the UN's Sustainable Development Goals.
A new $1.85 million grant will support a Phase 2 clinical trial of AMX0035, a combination of sodium phenylbutyrate and tauroursodeoxycholic-acid, to test its effectiveness in slowing or stopping brain cell death in people with mild cognitive impairment or Alzheimer's disease.
Researchers are studying the relationship between gut bacteria and Parkinson's disease, aiming to identify early signs of the illness. The study aims to compare the gut bacteria of people in the earliest stages of the disease with those who are healthy.
Researchers have developed a new class of drugs called PARP inhibitors to treat ovarian cancer by targeting synthetic lethality. These drugs aim to kill cancer cells by exploiting their genetic vulnerabilities, offering new hope to those with limited treatment options.
Researchers found that ceritinib, an FDA-approved drug for ALK-rearranged non-small cell lung cancer, also inhibits previously unknown targets. The study shows promise for repurposing the drug to target other cancers with networked alterations.
Monitoring blood levels of infliximab in IBD patients before loss of efficacy is associated with improved outcomes, including lower rates of surgery and hospitalization. This approach is linked to reduced treatment failure, infusion reactions, and need for IBD-related surgery or hospitalization.
The article explores how automation and innovative screens are influencing the search for inhibitors and activators of protein tyrosine phosphatases, which have been implicated in many human diseases. The resulting compounds are facilitating exploration of fundamental cellular processes controlled by phosphatases in cancers.
Researchers at Osaka University discovered that ivermectin, a medication for parasitic infections, also has an anti-tumor effect on epithelial ovarian cancer (EOC) cells. The gene target KPNB1 was identified as having oncogenic properties, and its inhibition induced apoptosis in EOC cells.
Researchers at the University of Pennsylvania have identified a new target for cancer therapies by blocking an enzyme crucial to tumor growth and a process that causes resistance to current treatments. A new drug called DQ661 successfully inhibits tumor growth in mice with melanoma, pancreatic, and colorectal cancers.
Researchers identified tau, a brain protein, as a potential target for stroke therapies. Mice deficient in tau showed significant protection from excitotoxic brain damage after experimental stroke, offering new avenues for treatment development.
Researchers have identified a zinc transporter, ZIP4, that is overexpressed in pancreatic cancer cells, making it a potential target for new drugs. The study reveals the structure of ZIP4's core, which conducts zinc transport, and identifies an unprecedented fold for membrane transporters.
Researchers have discovered that G protein-coupled receptors (GPCRs) are active in the cell interior, influencing gene transcription and cell division. This finding has implications for developing innovative drugs targeting receptor function or uptake.
A Penn-led study identified 16 new genes associated with type-2 diabetes and one new genetic risk factor for coronary heart disease. The researchers found that most of the sites known to be associated with higher diabetes risk are also linked to higher CHD risk, highlighting potential targets for future therapies.
Senolytic agents target senescent cells, which accumulate with age and contribute to chronic conditions like diabetes, cardiovascular disease, and cancer. Mayo Clinic researchers have identified new screening platforms to find additional senolytic drugs, potentially leading to transformative treatments for aging-related diseases.
A new study by Georgia Institute of Technology researchers has found that a widespread biological concept affecting cancer research could be incorrect up to two-thirds of the time. The study's findings suggest that targeting proteins based on messenger RNA levels may not be optimal, potentially leading to drug targeting errors.
A new study refines death certificate data to provide more accurate estimates of opioid and heroin fatalities, resulting in significant shifts in state-by-state mortality rates. The corrected rates show a 24% higher national growth rate for opioids and a 22% higher rate for heroin.
A team of researchers developed a novel biosensor to track drug uptake in cells, overcoming previous limitations. The sensors use fluorescent proteins to monitor drug presence and can be tailored for various enzymes of interest to the pharmaceutical industry.
Researchers have discovered a potential new treatment for delayed neuropathy caused by insecticides or chemical exposure. The study identified the TRPA1 channel as responsible for the condition and found that duloxetine and ketotifen alleviate symptoms in animal models.
Researchers at Rockefeller University have discovered two brain cell populations that regulate appetite and may offer a new path to treating obesity. The study found that activating specific neurons in the dorsal raphe nucleus can suppress hunger and promote weight loss, opening up new avenues for developing effective obesity drugs.
Researchers developed an algorithm that identifies the most influential people in social networks, known as 'hubs', and targeting them can effectively isolate a contagion. The approach shows promising results in controlling diseases like parasitic worm infections by treating fewer households.
A new screening method using CRISPR-Cas9 genome editing technology has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising class of cancer immunotherapy. The study identified Ptpn2 as a key gene that makes tumor cells more susceptible to PD-1 blockade.
A recent study analyzing over half of the malaria parasite's genes found that two thirds are essential for survival, opening up new avenues for antimalarial drug development. The researchers developed a method to decipher gene function by switching off and counting the growth of genetically modified parasites.
Researchers at Uppsala University develop a small-scale method to determine bioavailability of drugs within cells, facilitating early-stage drug development. The method takes into account how drugs 'disappear' when binding to cell components, offering a promising tool for pharmaceutical companies.
Researchers at UCSF developed a computational method to analyze open-access data and identify new treatments for cancer. The method, called Reverse Gene Expression Score (RGES), predicts drug efficacy by analyzing molecular characteristics of real tumors. Four drugs were identified with potential to treat liver cancer and other diseases.
Researchers at CNIO found that Plk1 inhibitors can cause hypertension and severe cardiovascular problems, suggesting a need for more thorough studies on protein functions. The study used laboratory mice to model human diseases, revealing the critical role of Plk1 in maintaining blood pressure.
Researchers at The Francis Crick Institute and The London School of Hygiene & Tropical Medicine identified a key protein involved in malaria parasite escape. Disrupting this protein reduces the efficiency of parasite escape, slowing down infection rate.
A new study from Bentley University and Tufts University tracks the progress of developing new therapies for cardiovascular disease, finding that median time to first approval is greater than 40 years. The authors propose accelerating drug development by optimizing basic research and synchronizing it with growth.
Researchers have identified a promising therapeutic target for African trypanosomiasis, also known as sleeping sickness. The newly discovered TbALPH1 enzyme triggers the degradation of messenger RNA and is unique to the parasite's biology.
The article reviews current chemical search engines, named entity recognition and text mining systems to efficiently access biomedical data. Researchers emphasize the need for structured databases to process unstructured data in scientific literature, clinical reports, and patents.
Researchers found gilteritinib, an FLT3 inhibitor, to be a well-tolerated treatment that led to frequent clinical responses in patients with the FLT3 gene mutation, a common cause of relapsed leukemia. The drug showed promising results in a first-in-human study, with response rates tracking with the degree of FLT3 inhibition.
A newly described protein, PfAP2-I, regulates a number of genes involved with the parasite's invasion of red blood cells, making it an effective target for new antimalarial drugs. Preventing PfAP2-I from binding to DNA and initiating the expression of invasion genes could stop an infection before it reaches the red blood cell stage.
Scientists at Imperial College London discovered a way to target specific receptors controlling appetite in mouse brains without causing side effects. This breakthrough could lead to the development of a new type of anti-obesity medication that activates thyroid hormone receptors in the hypothalamus.
Researchers challenge existing understanding of MLL-translocation leukemia by finding that MLL2, not MLL, is the most appropriate target for drugs. The study shows that silencing wildtype MLL has no effect on disease development, but combining it with MLL2 knockout leads to significant reduction in leukemia.
Scientists develop new fluorescent imaging agents to detect enzyme activity in healthy and diseased tissues, enabling early disease identification and direct measurement of drug treatment effectiveness.
Researchers found that TB bacteria alter their metabolism to evade antimicrobials, but new drugs targeting these 'escape pathways' could lead to shorter treatments. This approach aims to improve compliance and reduce the emergence of drug-resistant germs.
A Dutch scientist has designed a nanomotor that can deliver and release drugs for cells, triggered by glutathione, a chemical signal inside cells. The nanomotor uses hydrogen peroxide to propel itself across the cellular membrane and releases its cargo upon encountering higher concentrations of glutathione.
Studies show a prevalence rate of 50-82% among hospitalized patients in Egypt's largest cities, while community-acquired MRSA rates range from 19-47%. Molecular characterization reveals various SCCmec types, highlighting the need for national surveillance and awareness.
Diabetes-induced changes in heartbeat are primarily regulated by the β1-adrenoceptor, suggesting that targeting this receptor could improve treatment outcomes for diabetics. The study provides novel insight into the pathological basis of heart rate dysregulation in type 2 diabetes.
Researchers at OIST created self-assembling molecules that can be rearranged by ultraviolet light to form novel macroscopic structures. This breakthrough enables the creation of exotic nanostructures with tailored functions, holding potential for biological and pharmaceutical applications.
Scientists identified a key gene, MDR1, governing toxin removal in the gut, which is linked to bowel disorders like Crohn's disease. Targeting vital cell parts with drugs can reverse damage and improve outcomes.
A proof-of-principle study found that imatinib improved airway hyperresponsiveness and decreased mast cell presence in patients with severe asthma. Treatment also showed a small improvement in airway function.
Researchers at Massachusetts General Hospital found that a diverse gut microbiome can predict treatment response for IBD patients. The study suggests that early changes in the microbial population can identify patients likely to achieve and maintain remission.
A team of researchers at Osaka University used advanced technology to investigate the interaction between anti-TNF drugs and tumor necrosis factor (TNF). They found that the size and shape of the TNF-drug complexes differ among three tested drugs, with implications for predicting therapeutic effects and optimizing drug design.
A new study from Bentley University found that most new drugs approved by the FDA since 2010 arose from basic scientific research initiated in the 1970s or 1980s. The development of targeted and biological therapeutics depends on achieving a certain level of maturation in basic science.
University of New Mexico researchers have discovered a method to optimize network processes, reducing energy consumption and effort required to achieve desired results. By focusing on key elements rather than monitoring all elements, the effort can be reduced dramatically, leading to significant cost savings and improved performance.
A new algorithm, CYCLOPS, can detect and characterize molecular rhythms in human cells. The tool has the potential to improve dosing for many existing medications by identifying optimal times for administration.
An international team of scientists has determined the 3-D atomic structure of over 1,000 proteins that are potential drug and vaccine targets. The experimentally determined structures have been deposited into the World-Wide Protein Data Bank, freely available to the scientific community.
Researchers found that combination therapy is only beneficial for high-risk patients with CPE, while low-risk patients can be treated with a single active antimicrobial. This approach reduces adverse side effects and the risk of drug resistance.
Researchers have developed a way to deliver drugs to specific types of neurons in the brain, allowing for more precise study and treatment of neurological diseases. The new method, DART, reveals how movement difficulties in Parkinson's Disease are controlled by the AMPA receptor, offering a new approach to treating the disease.
Researchers have developed a new technique that allows for precise mapping of cellular signaling networks involved in human biology and disease. This breakthrough opens up exciting avenues for understanding and treating psychiatric diseases, including opioid addiction.
Rutgers scientists determine the structure of tuberculosis drug target Mtb RNA polymerase and discover a new class of compounds, Na-aroyl-N-aryl-phenylalanamides (AAPs), that potently inhibit it. The findings reveal potential for developing improved anti-tuberculosis drugs.
Researchers have discovered new structural details of the angiotensin II receptor AT2R using X-ray free electron laser technology. The findings could speed the development of new compounds addressing cardiovascular conditions, neuropathic pain and tissue growth.
Researchers discovered new structural details of an angiotensin II receptor called AT2, which could be a target for new medicines. The information uncovered could give drug developers a new path for compounds that combat pain and inflammation or promote tissue regeneration.
Scientists discovered that nerve cells in ganglia can exchange information and modify sensory input to the central nervous system. This finding has potential implications for developing non-addictive painkillers targeting the peripheral nervous system.
KinderMiner, a Morgridge Institute for Research team's algorithm, scans Europe PubMed Central and provides ranked associations for select target terms and key phrases. The tool identifies relevant transcription factors in top 20 hits, significantly speeding up scientific process.
Scientists have identified two parasite proteins that allow Plasmodium falciparum malaria parasites to quickly traverse human cells and infect liver cells. This discovery could lead to the development of new antimalarial treatments and vaccines to combat the disease.
A new mathematical model of Plasmodium falciparum's metabolism reveals its essential genes and thermodynamic bottlenecks, enabling potential mechanisms to target with drugs. The model integrates genetics and metabolomics data, allowing for the formulation of testable hypotheses and accelerating novel antimalarial drug discovery.
Researchers developed a comprehensive mathematical model of the deadliest malaria parasite Plasmodium falciparum metabolism. The model accurately integrates genetics and metabolism data, predicting which genes are indispensable for every biological function in the parasite.
Scientists have developed a shorter treatment regimen using rifampicin to target Wolbachia, reducing treatment times for lymphatic filariasis (LF) and onchocerciasis (Oncho) to just 1-2 weeks. This regimen is safe for pregnant women and children, offering a more effective and accessible solution to these debilitating diseases.
The DrugAge database, the largest such database in the world, has been announced by scientists from the Biogerontology Research Foundation and University of Liverpool. The database contains 418 compounds targeting various age-related pathways, revealing that most have yet to be targeted pharmacologically.